Latest Breaking News On - Phase 2 tacti 002 trial - Page 1 : comparemela.com

Bernard Doger de Spéville, MD, PhD, discusses key findings from part C of the phase 2 TACTI-002 trial of eftilagimod alpha plus pembrolizumab as second-line treatment for patients with head and neck squamous cell carcinoma.

Spain
Madrid
Fundacion-jimenez-diaz
Early-phase-clinical-trials-unit
Phase-2-tacti-002-trial-
Ct03625323-
Eftilagimod-alpha
Pembrolizumab
Head-and-neck-squamous-cell-carcinoma
Hnscc
Bernard-doger-de-spéville